

Extended Patent Protection for Strangvac® approved in the United Kingdom

Stockholm, September 20, 2024 – Intervacc AB (publ) announces that the application for supplementary protection for Strangvac®, an innovative vaccine against strangles, has now been approved in the United Kingdom. This supplementary protection extends the existing patent protection from May 2031 to May 2036 on the UK market.

The previously approved European patent for Strangvac® is valid until May 2031. With the newly granted supplementary protection in the United Kingdom, along with previous applications in other European markets including Sweden, Benelux, Italy, Ireland, France, Spain, Germany, and Austria, we have high hopes that the protection for Strangvac® will be extended and valid until May 2036 across Europe. Vaccines typically have a long product lifecycle, and the risk of someone developing a biosimilar to a vaccine once the patent has expired is minimal. In both the EU and the USA, there are specific regulations for approving biosimilars, and none of the more than 130 approved biosimilars relate to a, veterinary or human vaccine.

Supplementary protection, or Supplementary Protection Certificate (SPC), is an intellectual property right that acts as an extension of patent protection. It is specifically designed for pharmaceutical and plant products that are protected by patents and have been approved for sale by the European Commission. This protection aims to compensate the patent holder for the time required to meet extensive regulatory requirements before marketing authorization can be granted.

"We are very pleased to have received this supplementary protection approval in the United Kingdom. It provides us with an important extension of our patent protection in one of our key markets," commented CEO Jonas Sohlman, adding, *"We believe that Strangvac® will become the leading vaccine against strangles globally and will continue to contribute to improved animal health long after the patent and supplementary protection have expired."*

For more information please contact:

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on September 20, 2024, 8.30 a.m. CET.

About equine strangles

Equine strangles, caused by the bacterium *Streptococcus equi*, is a severe, common and highly contagious infectious disease that effect horses. Strangles is endemic in horse populations worldwide, with the exception of Iceland.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10